Life Sciences & Biotechnology
Title : | Development of Novel Purine Nucleoside-Quinoline Conjugates as Effective Inhibitors for Chikungunya and Dengue Viruses |
Area of research : | Life Sciences & Biotechnology |
Focus area : | Medicinal Chemistry |
Principal Investigator : | Dr. Rakesh Kumar, Dr. B R Ambedkar National Institute of Technology Jalandhar, Punjab |
Timeline Start Year : | 2024 |
Timeline End Year : | 2027 |
Contact info : | rakeshccny@gmail.com |
Details
Executive Summary : | The re-emergence of vector-borne infections, such as Chikungunya and Dengue, poses a significant health and economic threat worldwide. India, being a densely populated country, is prone to infection outbreaks. The lack of an approved vaccine for these viruses makes the situation vulnerable. Quinoline, a privileged scaffold in medicinal chemistry, remains the preferred pharmacophore in antiviral drug design. Quinoline-derived antimalarial drug, chloroquine, has been reported to inhibit these viruses. Nucleoside analogs are another important class of broad-spectrum antivirals that have shown potency against these viruses. The conjugation of nucleoside scaffolds to bioactive molecules has shown to significantly improve their bioactivity. Novel quinoline-purine nucleoside conjugates (adenosine and deoxyadenosine) conjugates are proposed as effective CHIKV and DENV inhibitors. The study will use an environmentally friendly approach to access a library of novel adenosine and deoxyadenosine conjugates of quinoline N-oxides. Molecular docking studies will be performed with viral proteins to understand their interactions and assess structure activity relations for designing effective inhibitors. Antiviral activities will be assessed through cell-based antiviral assays using previously isolated strains. |
Co-PI: | Prof. shailly Tomar, Indian Institute of Technology Roorkee, Uttarakhand,Roorkee (247667) |
Total Budget (INR): | 44,06,000 |
Organizations involved